stockrowiBio, Inc.
IBIO Healthcare Biotechnology
iBio, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $100,000.00, down 75.0% from fiscal 2025.
- Revenue
- +100.0%
- EPS
- +80.5%
- Free cash flow
- −35.3%
Quarter to June 2026, against a year earlier
Follow IBIO
Alert me
iBio, Inc. (IBIO) EV/Sales
As of 6 November 2026, iBio, Inc. (IBIO) trades at a EV/Sales of −12.8×. Over the past ten years it has ranged from −19.0× (October 2026) to 375× (February 2026); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 141× | 10,053.64% |
| FY2025 | 1.4× | — |
| FY2024 | −2.9× | — |
| FY2022 | 24.8× | (74.60%) |
| FY2021 | 97.5× | 36.26% |
| FY2020 | 71.6× | 330.86% |
| FY2019 | 16.6× | (59.52%) |
| FY2018 | 41.0× | (68.74%) |
| FY2017 | 131× | 105.39% |
| FY2016 | 63.9× | 102.40% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | −6.3× | — |
| Jun 2025 | 1.4× | (96.39%) |
| Dec 2024 | 38.6× | — |
| Jun 2024 | −2.9× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. | −12.8× |
| CRBU Caribou Biosciences, Inc. compare | −5.0× |
| BMEA Biomea Fusion, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| HYFT MindWalk Holdings Corp. compare | 4.1× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 4.9× |
| SER Serina Therapeutics, Inc. compare | 32.5× |
| GANX Gain Therapeutics, Inc. compare | 154× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)